Structure-based Antiviral Design against HTLV-1 Protease
基于结构的 HTLV-1 蛋白酶抗病毒设计
基本信息
- 批准号:10750889
- 负责人:
- 金额:$ 3.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVActive SitesAdultAdult T-Cell Leukemia/LymphomaAdvisory CommitteesAdvocateAffectAffinityAmino Acid SequenceAntiviral AgentsAspartic EndopeptidasesBindingBiochemicalBiological AssayCarcinogensCommunitiesCrystallographyDiseaseEnvironmentEvolutionFamilyHIVHIV ProteaseHIV-1HIV-1 proteaseHIV/HCVHealthHepatitis C virusHumanHuman T-lymphotropic virus 1IndividualInfectionInflammatoryInvestigationLaboratoriesLeadLife Cycle StagesMolecularMutationOncogenicPatientsPeptide HydrolasesPersonsPolyproteinsPopulationPositioning AttributePrevalenceProtease InhibitorProteinsRelapseReportingResearchResistanceRetroviridaeSARS coronavirusSeriesShapesSiteSpecificityStructureSubstrate InteractionSubstrate SpecificityT-Cell LymphomaTechniquesTestingTrainingTranslatingVaccinesViralViral ProteinsVirusX-Ray Crystallographyanalogchronic infectiondesignexperienceinfection rateinhibitorinsightlaboratory experiencemetermolecular dynamicsnovelpressurepreventprotease Soprotein purificationrational designskills
项目摘要
Project Summary
Human T-cell leukemia virus type-1 (HTLV-1) is an oncogenic human retrovirus affecting over 20 million people
worldwide. HTLV-1 infection can cause adult T-cell lymphoma (ATL) and other serious inflammatory diseases.
Estimates report that 5-10% of HTLV-1 infected patients will develop a serious condition such as ATL, which has
poor 4-year survival and high relapse rates. HTLV-1 has persistent infection rates across the globe and reaches
up to 45% prevalence in certain communities. Despite this impact on human health, there are no direct-acting
antivirals (DAAs) or vaccines against HTLV-1. HIV-1 and HTLV-1 are from the same viral family and encode for
a homodimeric aspartyl protease crucial for cleavage of functional proteins from viral polyproteins. The activity
of HIV-1 and HTLV-1 protease is essential to their viral life cycles. The Schiffer laboratory has extensive
experience with viral protease crystallography and inhibition, especially with viral proteases for HIV-1, HCV
NS3/4A, and SARS-CoV-2 main protease. This expertise uniquely positions me to design, synthesize, and
characterize potent, resistance-thwarting protease inhibitors against HTLV-1 protease. Resistance-preventing
DAA design is essential because of the selective pressure applied during DAA treatment. An ideal and proven
strategy for developing a highly potent and resistance-preventing viral protease inhibitor is to target the active
site through rational design using the substrate envelope. The substrate envelope for HTLV-1 protease has not
been characterized and we lack a detailed understanding of the protease substrate specificity. I hypothesize that
by translating strategies from our design of HIV-1 protease inhibitors, namely characterizing HTLV-1 protease’s
substrate specificity, I can design potent and resistance-preventing DAAs for HTLV-1 protease.
Aim 1: Characterize the structural basis for HTLV-1 protease substrate specificity. HTLV-1 protease
cleaves six substrates by recognizing cleavage sites between individual proteins of the viral polyprotein. I will
investigate the molecular basis of this recognition underlying protease specificity by determining cocrystal
structures of the protease with bound substrates. The conserved volume inhabited by the substrates will define
the substrate envelope and inform inhibitor design for HTLV-1 protease. Aim 2: Rationally design, synthesize,
and characterize inhibitors of HTLV-1 protease to optimize potency. HIV-1 and HTLV-1 proteases share an
active site amino acid sequence identity of 45% and high structural similarity. Therefore, I will begin inhibitor
design by testing a selection of our in-house HIV-1 protease inhibitors, which have already shown low (1 µM) to
moderate (30 nM) potency against HTLV-1 protease. I will combine experimental inhibition assays with cocrystal
structure analysis to identify lead compounds for inhibitor design. I will leverage substrate specificity of the
protease by moving inhibitor design towards compounds that mimic the shape of substrates, leveraging the
substrate envelope (Aim 1), and the interactions between protease and substrate. I aim to produce novel, highly
potent (sub-nM) inhibitors that will be promising DAAs for further investigation against HTLV-1.
项目摘要
人类T细胞白血病病毒1型(HTLV-1)是一种致癌性人类逆转录病毒,感染人数超过2000万
全世界。HTLV-1感染可导致成人T细胞淋巴瘤(ATL)和其他严重的炎症性疾病。
据估计,5%-10%的HTLV-1感染者将发展为ATL等严重疾病,这种疾病已经
4年存活率低,复发率高。HTLV-1在全球范围内具有持续的感染率,并
在某些社区中的流行率高达45%。尽管对人类健康有这种影响,但没有直接作用于
抗HTLV-1的抗病毒药物(DAA)或疫苗。HIV-1和HTLV-1来自同一个病毒家族,编码
一种同源二聚体天冬氨酸蛋白酶,对从病毒多蛋白中切割功能蛋白至关重要。活动
HIV-1和HTLV-1蛋白酶的活性对它们的病毒生命周期是必不可少的。希弗实验室拥有广泛的
病毒蛋白水解酶结晶学和抑制经验,尤其是HIV-1、丙型肝炎病毒的病毒蛋白水解酶
NS3/4A和SARS-CoV-2主要蛋白水解酶。这种专业知识使我在设计、合成和
鉴定针对HTLV-1蛋白酶的有效的、抗药性受阻的蛋白酶抑制剂。防病防病
DAA的设计是必不可少的,因为在DAA治疗过程中施加了选择性压力。一个理想而又久经考验的
开发高效和抗药性病毒蛋白水解酶抑制剂的策略是针对活性
网站通过合理设计,采用了衬底封套。HTLV-1酶的底物包膜还没有
但我们对其底物的专一性缺乏详细的了解。我假设
通过将我们设计的HIV-1蛋白酶抑制剂的策略转化为HTLV-1蛋白酶的特征
根据底物的特异性,我可以设计出针对HTLV-1蛋白酶的有效的、耐药的DAAs。
目的1:研究HTLV-1蛋白酶底物专一性的结构基础。HTLV-1蛋白酶
通过识别病毒多蛋白的单个蛋白质之间的裂解位置来裂解六种底物。这就做
通过确定共晶体来研究这种识别的分子基础,其潜在的蛋白酶特异性。
具有结合底物的蛋白酶的结构。底物所占据的保守体积将定义
HTLV-1蛋白水解酶底物包膜及信息抑制剂设计。目标二:合理设计、综合、
并对HTLV-1蛋白酶抑制剂进行表征,以优化效力。HIV-1和HTLV-1蛋白酶共享一个
活性部位氨基酸序列同源性为45%,结构相似性高。因此,我将开始抑制
通过测试我们精选的一系列内部HIV-1蛋白酶抑制剂进行设计,这些药物已经显示出低(1微米)到
对HTLV-1蛋白酶的中等效力(30 NM)。我将把实验性的抑制试验与共晶体结合起来
结构分析以确定用于缓蚀剂设计的先导化合物。我将利用底物的专一性
通过将抑制剂设计移动到模仿底物形状的化合物上,利用
底物包膜(目标1),以及蛋白酶与底物之间的相互作用。我的目标是制作新奇的,高度的
有效的(亚纳米级)抑制剂,有望为进一步研究HTLV-1提供DAA。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah N Zvornicanin其他文献
Sarah N Zvornicanin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334970 - 财政年份:2024
- 资助金额:
$ 3.5万 - 项目类别:
Standard Grant
NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
- 批准号:
2400195 - 财政年份:2024
- 资助金额:
$ 3.5万 - 项目类别:
Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
- 批准号:
2334969 - 财政年份:2024
- 资助金额:
$ 3.5万 - 项目类别:
Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
- 批准号:
23K04919 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
- 批准号:
22KJ2957 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
- 批准号:
23K04494 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
- 批准号:
23K13831 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
- 批准号:
2238379 - 财政年份:2023
- 资助金额:
$ 3.5万 - 项目类别:
Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
- 批准号:
2154399 - 财政年份:2022
- 资助金额:
$ 3.5万 - 项目类别:
Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
- 批准号:
RGPIN-2019-06633 - 财政年份:2022
- 资助金额:
$ 3.5万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




